To validate these results, we examined PSG9 protein levels in nine pairs of matched adjacent normal breast tissues, primary breast tumors, and metastatic lymph node (LN) tissues by immunoblotting with an anti‐PSG9 antibody. This evidence concerns the gene PSG9 and breast neoplasm.